Jaina Patel was in her early 30s when a bout of bronchitis led to hear losing weight, her job and eventually her sense of ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Dupilumab reduced airway inflammation and mucus burden and enhanced airway volume and flow, which led to better lung function and improved asthma control in patients with moderate to severe type 2 ...

Source Reference: Lugogo NL, et al "Characterization of patients with asthma treated with dupilumab in a real-world setting: The RAPID registry" CHEST 2022; DOI: 10.1016/j.chest.2022.08.2185.

Key takeaways: Asthma exacerbation rates ranged from 0.91 to 1.37 for the placebo group and from 0.32 to 0.58 for the dupilumab group. Exacerbations peaked in winter with placebo and in autumn ...

Between dupilumab and benralizumab, researchers found a significantly reduced rate of asthma exacerbations in the dupilumab group (1.07 per year vs. 1.47 per year; rate ratio, 0.73; 95% CI, 0.63-0 ...

Berger P, Menzies-Gow A, Peters AT, et al. Long-term efficacy of dupilumab in asthma with and without chronic rhinosinusitis and/or nasal polyps. Ann Allergy Asthma Immunol . Published online ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with ...

Meeting Coverage > AAAAI Dupilumab Cuts Lung Inflammation, Breaks Up Mucus Plugs in Asthma Patients — In VESTIGE trial, IL-4/IL-13 blocker also improved airway volumes and airflow ...

Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.